Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months - a post-hoc analysis of a randomised trial

被引：0
|
作者：
Wong, S. [1 ]
Miller, K. [2 ]
Smith, M. R. [3 ]
Dearnaley, D. [4 ]
Dogliott, L. [5 ]
Egerdie, B. [6 ]
Fizazi, K. [7 ]
Kueppers, F. [8 ]
Montes De Oca, L. [9 ]
Morote, J. [10 ]
Pavlik, I. [11 ,12 ]
Sieber, P. [13 ]
Tammel, T. J. [14 ]
Van Poppel, H. [15 ]
Wirth, M. [16 ]
Ye, Z. [17 ]
Braun, A. [17 ]
机构：
[1] Western Hosp, Footscray, Vic, Australia
[2] Charite, Berlin, Germany
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[5] Osped San Luigi Gonzaga, Orbassano, TO, Italy
[6] Urol Associates, Urol Med Res, Kitchener, ON, Canada
[7] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[8] Canterbury Urol Res Trust, Christchurch, New Zealand
[9] Ctr Diagnost Urol, Buenos Aires, DF, Argentina
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Gen Teaching Hosp, Urol Clin, Prague, Czech Republic
[12] Fac Med 1, Prague, Czech Republic
[13] Urol Associates Lancaster, Lancaster, PA USA
[14] Tampere Univ Hosp, Tampere, Finland
[15] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[16] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[17] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [31] Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
    Bellmunt, Joaquim
    Kheoh, Thian
    Yu, Margaret K.
    Smith, Matthew R.
    Small, Eric J.
    Mulders, Peter F. A.
    Fizazi, Karim
    Rathkopf, Dana E.
    Saad, Fred
    Scher, Howard I.
    Taplin, Mary-Ellen
    Davis, Ian D.
    Schrijvers, Dirk
    Protheroe, Andrew
    Molina, Arturo
    De Porre, Peter
    Griffin, Thomas W.
    de Bono, Johann S.
    Ryan, Charles J.
    Oudard, Stephane
    EUROPEAN UROLOGY, 2016, 69 (05) : 924 - 932
  • [32] WHAT ARE THE BEST CUT-POINTS FOR PSA DOUBLING TIME IN MEN WITH NON-METASTATIC CASTRATIONRESISTANT PROSTATE CANCER?
    Howard, Lauren
    Moreira, Daniel
    De Hoedt, Amanda
    Aronson, William
    Kane, Christopher
    Amling, Christopher
    Cooperberg, Matthew
    Terris, Martha
    Freedland, Stephen
    JOURNAL OF UROLOGY, 2017, 197 (04): : E246 - E247
  • [33] PROSPER: A phase 3 study of enzalutamide (ENZA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
    Tombal, B.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N. D.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    SWISS MEDICAL WEEKLY, 2018, 148 : 15S - 15S
  • [34] Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA
    Delanoy, N.
    Robbrecht, D.
    Fizazi, K.
    Mercier, F.
    Sartor, O.
    De Wit, R.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).
    Li, Sophia
    Ding, Zhijie
    Lin, Jennifer H.
    Behl, Ajay S.
    Pericone, Chris
    Macomson, Brian
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [36] Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).
    Li, Sophia
    Ding, Zhijie
    Lin, Jennifer H.
    Behl, Ajay S.
    Pericone, Chris
    Macomson, Brian
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC)
    Nakabayashi, M.
    Oh, W. K.
    Werner, L.
    Xie, W.
    Regan, M. M.
    McKearn, T. J.
    Kantoff, P.
    Pomerantz, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective
    Huang, Po-Chieh
    Huang, Li-Hua
    Yang, Cheng-Kuang
    Li, Jian-Ri
    Chen, Chuan-Shu
    Wang, Shian-Shiang
    Chiu, Kun-Yuan
    Ou, Yen-Chuan
    Lin, Chia-Yen
    PLOS ONE, 2024, 19 (08):
  • [39] Real-world Clinical Outcomes in Non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) Patients in Australia
    Gupta, Karan
    Goh, Jeffrey
    Gan, Chun
    Anton, Arsha
    Weickhard, Andrew
    Azad, Arun
    Uccellini, Anthony
    Brown, Stephen
    Wong, Shirley
    Parente, Phillip
    Shapiro, Julia
    Liow, Elizabeth
    Torres, Javier
    Parnis, Francis
    Steer, Christopher
    Warren, Mark
    Gibbs, Peter
    Tran, Ben
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 93 - 94
  • [40] Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.
    de Velasco, Guillermo
    Lora, David
    Carretero-Gonzalez, Alberto
    Martin Soberon, Maria Cruz
    Sepulveda Sanchez, Juan Manuel Manuel
    Lorente, David
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345